A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Pazopanib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 29 Aug 2019 Planned End Date changed from 30 Jun 2019 to 31 Dec 2019.
- 29 Aug 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Dec 2019.
- 12 Feb 2019 Status changed from recruiting to active, no longer recruiting.